The combination of CDK4/6 inhibitors with other agents might be a more effective strategy to improve clinical outcomes and to extend the use of CDK4/6 inhibitors to a broader spectrum of breast and ovarian cancer patients than CDK4/6i alone. This evidence concerns the gene CDK4 and ovarian cancer.